In recent years, a cultural change in the handling of data from Background: research has resulted in the strong promotion of a culture of openness and increased sharing of data. In the area of clinical trials, sharing of individual participant data involves a complex set of processes and the interaction of many actors and actions. Individual services/tools to support data sharing are available, but what is missing is a detailed, structured and comprehensive list of processes/subprocesses involved and tools/services needed.
Introduction
In recent years, a cultural change in the handling of research data has resulted in the strong promotion of a culture of openness and increased sharing of data. Many organisations, initiatives and projects have expressed their commitment to support open scientific research. This move has been extended also to clinical trials. Today, the results of clinical trials are more and more considered as a public good, and access to the individual participant data (IPD) generated by those trials is seen as part of a fundamental right to health data (see Research Councils UK principles on data policy).
To support data sharing in clinical trials, several organisations have developed generic principles, guidance and practical recommendations for implementation in recent years (e.g. the Institute of Medicine report in the US 1 , the Nordic Trial Alliance Working Group on Transparency and Registration for the Nordic countries 2 , the good practice principles for sharing IPD from publicly funded trials by MRC, UKCRC, CRUK and Wellcome, in the UK 3, 4 , or the guide to publishing and sharing sensitive data for Australia 5 ). Within the EU Horizon 2020 funded project CORBEL (Coordinated Research Infrastructures Building Enduring Life-science Services) and coordinated by the European Clinical Research Infrastructure Network (ECRIN), an interdisciplinary and international stakeholder taskforce reached a detailed consensus on principles and recommendations for data sharing of clinical trial data 6 . That document was taken as the starting point for the current paper.
Data sharing of IPD from clinical trials involves a complex set of processes and the interaction of many actors and actions. Some documentary support is available, (e.g. templates for data sharing plans, data transfer and data use agreements), but this is scattered and thus not always easy to find. In addition, although some IT-tools and services are available to give support for individual tasks in the process of data sharing (e.g. de-identification service for datasets; see Electronic Health Information Laboratory page on de-identification software) or an ID-generation service for study objects), these are again difficult to discover and their quality is not easy to explore. An additional aspect of complexity stems from the very heterogeneous set of repositories that are available for storage of IPD (see Registry of Research Data Repositories). There are general scientific repositories, repositories dedicated specifically to clinical research, repositories specialised in storing data related to a specific disease area and institution-specific repositories. In summary, although fragments of infrastructure are available to support sharing of IPD from clinical trials, the various services and tools are scattered and a global vision of how all these components should interact and interoperate does not currently exist.
What is still missing is a generic framework or architecture for data sharing that could be used for modelling, describing, and designing operations, data requirements, IT-systems and technological solutions (see Open Group TOGAF® framework). Such a framework would link structural concepts (e.g. actors) with behavioural concepts (e.g. processes linked to services) giving an overview of how actors, processes and services interact to form a system for data sharing of IPD. Due to its complexity with many different processes and actors, such a framework is not available at the moment. As a first step in creating such a framework, in this paper we provide a systematic, structured and comprehensive list of processes/ subprocesses linked to data sharing derived from our CORBEL consensus document.
Methods
Recommendations and principles from the data sharing consensus document were analysed in detail and individual processes/ subprocesses identified and linked to actors and possible services/ tools by a small group of experts (CO, SC, RB, WK, SB). The consensus document covers all stages of the data sharing life cycle and is highly structured, with 7 main topics, 10 principles assigned to these topics and 50 specific recommendations, making the analysis process relatively straightforward 6 . The specification of processes/subprocesses, actors and services/tools was agreed between the experts in telephone conferences and by written communication, and summarized in a table with listings.
In the next step, possible services/tools associated with single processes/subprocesses were analysed and grouped according to different types of support, preserving reference to the processes/ subprocesses specified in the first step.
The following definitions were adapted from the business process model and notation (BPMN) and applied to our analysis (see Object Management Group page, 7):
Process:
A sequence or flow of activities in an organization with the objective of carrying out work (see Object Management Group page).
In this study, processes may relate to different organisations and business goals, e.g. the various activities of the data generators, data storage managers and secondary users all represent different business processes, operating at different times by different actors. 
Subprocess

Subservice:
A subservice is a special case of a service (see Open Science and Research framework)
To keep things as simple as possible, processes were structured according to the main activities within data sharing of IPD and then further differentiated with respect to subprocesses. For every process the involved actors and possible tools/services are linked.
For graphical illustration, the BPMN approach was used. In BPMN, a process is depicted as a graph of flow elements, which are a set of activities, events, gateways, and sequence flow that adhere to a finite execution semantics. The usual BMBP notation and symbols were taken (event, activity, gateway, connections, swim lane) (see Object Management Group page). In this publication, BPMN is used only to give a high-level overview on the relation between the main processes.
Results
From the analysis of the consensus document 9 main processes involved in data sharing of IPD were identified:
1. Preparation for data sharing, in general 2. Plan for data sharing, in the context of a specific trial 3. Preparation of data for sharing, after data collected 4. Transferring data objects to an external repository 5. Repository data and access management 6. Access to individual participant data and associated data objects 7. Discovering the data objects available 8. Publishing results of re-use 9. Monitoring data sharing Process 1 to 5 can be summarized under the heading "Data preparation and storage", the processes 6-9 under the heading "Data request and secondary analysis". The relationship between the main processes is presented in Figure 1 .
The main processes were structured further into more detailed processes/subprocesses and linked to actors involved and possible services/tools. As result a detailed and comprehensive list of individual processes/subprocesses involved in data sharing is given in Table 1. In Table 2 , possible services/tools associated with processes are grouped according to major types of support, preserving reference to the processes/subprocesses. As the table illustrates, these tools and services fall into 6 (overlapping) categories: 
Data objects:
any discrete packages of data in an electronic form -whether that data is textual, numerical, a structured dataset, an image, film clip, (etc.) in form. They are each a file, as that term is used within computer systems, and are named, at least within their source file system. In the context of clinical research and data sharing, data objects can include electronic forms of protocols, journal papers, patient consent forms, analysis plans, and any other documents associated with the study, as well as datasets representing different portions and types of the data generated, and the metadata describing that data.
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Authentication:
The process of ensuring that a person or system that is trying to access a system is who they say (it says) they are. With a person, authentication is by provision of one or more of something only they should know (e.g. a password), or should have (e.g. a card or fob), or can show (e.g. fingerprint, iris pattern). With a system it is more often by provision of a secret token (in effect a machine password), often derived from public key cryptography.
Authorisation:
The process of giving an authenticated entity the rights to access particular subsets of data and/or to carry out particular functions within a system. It is usually carried out by assigning user entities to roles and to groups that together define the access allowed. Reference to process (Table 1) 1. Providing general background material Providing general background material Collection of relevant resources about data sharing in general -e.g.
• Links to papers and relevant policy documents from an annotated bibliography,
• Summary documents (e.g. built around recent consensus paper) and web pages • Glossary of terms • Links to general educational and training resources provided elsewhere • Courses, webinars, books using materials above • Meetings, conference sessions looking at aspects of data sharing and related topics • Advice to citizens, ethics committees 1.1.1
Locator services
Locator service for data sharing resources Resource identification -Especially of
• Repositories for storage of datasets and other data objects, and their facilities, terms of service etc.
• Services to aid in de-identification • Provides information on the applicable legal framework • Provides model agreements templates that can be adapted to meet the particular circumstances of data sharing projects.
1.1.2
Locator service for data standards resources Annotated Links to
• Repositories of standard data items, e.g. within CDISC's CDASH, CFAST.
• Repositories of standard data instruments, e.g. CDISC QRS (questionnaires, ratings and scales)
• Metadata schemes • Core outcome sets (e.g. COMET)
1.3.2, 2.5
Example documents
Example documents supporting data sharing processes
• Example SOPs, • Supporting relevant checklists, forms Covering all aspects of data sharing, e.g.
• during study preparation, or as part of long term data management, in the context of pre-defined collaborations, or when handling requests for access.
• Use of data standards in study design • Use of metadata for data description, data object discovery • Examples of data sharing policies (universities, research institute)
• Examples of data sharing requests from funders or journals 5.6, 5.7, 6.1.5
Services
De-identification / anonymisation service for datasets There are four possible services here -
• Resources that allow trials units to develop their own de-identification/anonymisation processes (if compliant with legal considerations).
• Consultancy input to advise on de-identification in the context of a particular trial • Services that carry out and document a de-identification process on behalf of the sponsor / trials unit • Service for assessment of risk of re-identification Descriptive metadata services for datasets To be useful (easily searchable, comparable etc.) the descriptive metadata of the data needs to be in a standard format, or one of a few recognised standard formats (e.g. CDISC ODM). Mechanisms and / or services to convert proprietary metadata descriptions into such a format could therefore be useful when required.
3.2.3, 3.3.2
Assessment / certification service for data repositories Provision of a set of standards, that can be used to assess the suitability of any repository as a location for data object storage, would act as a useful guide to the potential users of those repositories.
The further application of such standards within a certification scheme 4.4.1
An ID assignment mechanism for data objects An ID (e.g. doi) generation service is required for all stored data objects.
7.2
A common pipeline for processing access requests With the possibility of many different data repositories emerging storing clinical datasets, there is potential advantage from making the application, review, decision making process for each very similar (e.g. using common application proformas) or even managing those processes together, e.g. with a common expert advisory board.
This could ultimately create a common 'request pipeline'.
6.2.6
Recording and reporting systems for data access requests and episodes Reports that could be provided by repositories include
• Level and type of data object deposition
• The types of data access arrangements in place • Numbers and types of access requests • The decisions reached and reasons for rejections Data objects generated as a result of data re-use.
5.8, 6.2.7, 9.1
Provision of a prototype metadata repository A metadata repository, (or a portal linked to multiple such repositories) with discovery metadata for clinical trial data objects, is seen as a fundamental requirement if data sharing is going to work efficiently.
7.4, 7.5
Service for provision of a secure analysis environment Based on tools to provide an analysis environment for in-situ work (see below).
5.3
Type of service/tool Description/comments Reference to process (Table 1) 
Frameworks and guidance
The development of a discovery metadata schema Agreement is needed on a common discovery metadata standard that can link data objects to studies and that can describe the access mechanisms associated with each. Proposals have been made, based on an existing scheme (DataCite) but need further development.
4.2.4, 5.4, 7.1
The development of an agreed scheme for citation of re-use There needs to be a universally recognised scheme that will allow fair credit for the re-use of data, in terms of academic citation and recognition.
8.1.2
Legal and regulatory framework As the legal and regulatory environment continues to evolve, there is a need for updating the data sharing resources (e.g. templates, legal database, procedures). Similarly, the researchers and data managers has to be informed of any relevant changes in laws, regulations and data sharing policies/resources. Such a service could usefully be a central resource. It could not be a legal service as such (i.e. answering specific questions) but it could provide a general framework for guidance. 
Tools
Tools to support the application of discovery metadata scheme A tool is required to allow the easy application of the metadata schema used to characterize data objects, ideally by the object generators and if not by repository managers. This would likely take the shape of a set of web based forms, linked to a central repository. Provide an analysis environment for in-situ work Interest has been expressed in a mechanism that allows data to be examined, re-analysed, aggregated etc. without being downloaded first, but instead kept within a secured, tailored, 'analysis environment', which also contains the analysis tools required. In fact several different types of tools would be required, for:
• APIs to access repository catalogue data (for metadata aggregation) When discovery data is not (or has not been) directly transferred to a central repository using the tools described above, it will be necessary to try and 'harvest' metadata from data repositories on a regular basis. Using APIs that give access to the repository catalogues is a key part of that, and is much cheaper than trying to use 'data mining' techniques, e.g. natural language parsing on data object titles, to link data objects to studies.
5.4
Tools for generation of data transfer agreements/data use agreements Software tools supporting the development of data transfer/data use agreements (if compliant with legal considerations).
4.2
Discussion
Within the framework of the EU H2020 funded project CORBEL major issues associated with sharing of IPD were investigated and a consensus document on providing access to IPD from clinical trials was developed, using a broad interdisciplinary approach 6 . The taskforce reached consensus on 10 principles and 50 recommendations, representing the fundamental requirements of any framework used for the sharing of clinical trials data. To support the adoption of the recommendations, adequate tools and services are needed to promote and support data sharing and re-use amongst researchers, adequately inform trial participants and protect their rights, and provide effective and efficient systems for preparing, storing, and accessing data. As a first step on the way to inventory existing tools/services, their quality and applicability for data sharing, a systematic analysis of processes and actors involved in data sharing was performed. The work done resulted in a systematic, structured and comprehensive list of processes/ subprocesses that need to be supported to make data sharing a reality in the future. It is basic work against which existing tools/ services can be mapped, and gaps, where new tools/services are needed, can be identified.
In the context of this work, we explored the possibility of generating a generic framework for the sharing of IPD from clinical trials. As an example we considered the Framework for Open Science and Research by ATT (see Open Science and Research framework). This framework provides a general description of the desired architecture in a domain of open science. The framework configures and defines the key structural elements of the overall solution. It gives an overview of how various actors, research processes and services -including data, data structures, actors, roles and IT-systems -could form an interoperable system in the 'target' open state. The Enterprise Architecture (EA) approach is used, modelling, describing and designing operations, data requirements, IT-systems and technical solutions in accordance with a common model. The work done in developing a framework for open science and research could be of major relevance for a similar model in the area of data sharing. At this stage, of trying to basically structure processes/subprocesses involved in data sharing, it was seen as too early to develop a generic framework. It may, however, be that this approach is taken up again when the basic work has been done and the components for such a framework have been identified. Nevertheless, we thought it useful to use a standardised terminology and notation for describing basic processes in data sharing. This will simplify the extension to a more generic and comprehensive framework at a later stage. As one approach, business modelling has been applied successfully in the health and health research area. It has been used, for example, to perform a requirements analysis of the barriers to conducting research linking of primary care, genetic and cancer data 7 , to model the complexity of health and associated data flow in asthma 8 and to provide a generic architecture for a type 2 diabetes mellitus care system 9 . We decided not to apply the full spectrum of business process modelling (BPMN), but to use only basic elements to give a notational and terminological basis for further work. This does not imply, however, that the application of the full spectrum of BPMN techniques is a necessary step in developing an overall framework. More work is needed to explore the suitability and benefit of BPMN for a generic framework for data sharing.
Different models for clinical trials and clinical trials workflow already exist, such as the domain analysis model BRIDG 10 , the study design model CDISC SDM 11 and the primary care information model PCROM 12 . Any framework or model for data sharing needs to map or reference these clinical trial models, though none currently include the secondary use of data after the trial has completed. Although clinical trial processes and data sharing processes are distinct, they are clearly linked, and any models need to incorporate those linkages. As a consequence, developing a generic framework or architecture for data sharing needs much more work and is not covered in this paper.
Many of the services/tools identified in this paper are non-technical but nevertheless may be of major importance, especially for data generators and data requestors. This includes templates/examples, checklists and guidance. For some of the processes specified in this paper IT-tools and services already exist and can be applied (e.g. de-identification tools and services, see Electronic Health Information Laboratory page on de-identification software), others are under development or need improvement (e.g. metadata repository for identifying clinical trial objects, 13). The next step is to perform a scan on the availability and suitability of services/ tools for data sharing based on this work, with the involvement of stakeholders. We will summarize this information in a separate report.
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The valuable contribution of this work lies in the sequential structuring of data sharing tasks. Especially study groups who want (or have to) actively provide data have a checklist at hand, which gives them the opportunity to assess each sub-task in its complexity and to put together suitable persons or teams for implementation. This prevents important stakeholders from being overlooked or partial steps from being insufficiently taken into account, particularly with regard to regulatory issues.
The article focuses on aspects of data sharing in clinical trials, addressing a relevant problem of academic research, namely the long-term availability of research results in an environment that has only a limited lifespan due to project funding. It shows the complexity of the topic and every research group should already think about it during the project planning phase. Additionally, it is also relevant for other types of research projects, such as clinical registries, epidemiological cohorts or studies in health care research, with minor modifications.
I particularly liked the fact that aspects of providing analysis environments were also addressed, e.g. with special Docker containers that bring the evaluation algorithms to the data instead of releasing data.
The weak part of the paper is that even with a detailed listing of the sub-processes and the relevant tools, most researchers will find it difficult to design a concrete implementation strategy or to check whether the implementation meets the state of the art. Notes such as "Provide sample documents", "Assess risk of re-identification" or "Select suitable metadata schemas for object discovery" are simply too vague to be a real help. At this point, a knowledge base must be built up that provides researchers with concrete guidelines, implementation guidelines and example scenarios for successful projects.
Points to address:
The workflow in Figure 1 assumes that the data set is only imported once into an external repository. However, there are many scenarios in which data sets will have to be updated or extended, e.g. in long-running investigations where interim evaluations are already being carried out. Snapshots of shared data must be saved for verification purposes.
extended, e.g. in long-running investigations where interim evaluations are already being carried out. Snapshots of shared data must be saved for verification purposes.
Some years ago, there has been an EMA draft policy on publication and access to clinical-trial data . I'm not sure about the current status but it would be interesting to include the effort in this [1] paper.
Page 6, section 2.3.2 "Include request for broad consent for data sharing in informed consent documents." The term broad consent might require a more detailed definition, because in Germany consent is always contextual and without specific and the ethics committees are looking into this.
Metadata (sections 2.5, 5.4, 7.1) should not be limited to semantics and discovery. Another important topic for metadata is provenance metadata (measurement conditions, data quality, algorithms for calculated data) 
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This process-orientated manuscript covers a lot of ground in some detail. I have some specific comments:
Major
Section: General Comment: The process of reaching these recommendations is unclear to me. Perhaps these are opinions? I don't think there is primary evidence to underpin them. Should there be?
Section: General Comment: This is comprehensive, but also sets out a substantial burden on organisations. I wonder for what proportion of trials this work is proportionate effort.
Section: General Comment: This does not address my previous concerns about recognition of effort of the original researchers or issues about self-identification by patients, but perhaps that is outside of the scope of the paper. It would helpful to remind the reader that these are key, unresolved issues and point to places where they might be considered further. Section: Table 1 8.
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Section: The manuscript Classification of processes involved in sharing individual participant data from clinical trials by Ohmann C, Canham S, Banzi R, Kuchinke W and Battaglia S is more than useful for all stakeholders interested in data sharing. It must be accepted with, in my opinion, a few (and minor) edits.
In my experience as a researcher interested in the impact of data sharing policies , I have identified that a major practical barrier to implementation of full data sharing of randomised controlled trials was the great heterogeneity across different trial groups: "getting prepared and preplanning for data sharing still seems to be a challenge for many trial groups; data sharing proved to be novel for some authors who were unsure how to proceed". Therefore the description and classification of processes involved in sharing IPD from clinical trials will surely helps all stakeholders to get prepared. It is welcome and this manuscript will be very useful.
I have a few suggestions that may help to write it better. Please note that I'm not an expert in qualitative research. Therefore these are only suggestion that I don't want to enforce strongly.
First, as it is presented as a research paper and because it is very qualitative by nature, I would suggest to use, or better adapt the reporting guidelines for qualitative research to this specific paper as most points won't directly apply since the study presented is not a typical qualitative research. More specifically, I would welcome more details on authors in the main text: -Who are they? Were they from different background (e.g. data managers, statisticians, trialists, patients, etc..., Master degree, MD, PhD, PharmD... etc.). Please clearly state that they were involved in the initial initiative that was used for this paper . Please also detail how it could have affected their judgement.
-What is their background for conducting such a qualitative synthesis?
-Was there a protocol registered for this analysis?
Please specify why the processes were derived from only one initiative and not from a systematic assessment of other papers/initiatives. Any limitations of the initial paper should be discussed here. The process of analysis should be made as transparent as possible. How the different authors were involved in the process? Were there some leaders during the phone meetings? Were verbatim from written correspondence used? Was there a good agreement between expert (for what parts the agreement was less good ?)? The researchers' own position should also clearly be stated. A critical examination of their own role, possible bias, and influence on the research would be welcome.
I have also identified very practical points that could be addressed in a new version of the manuscript:
-In my very practical experience , figure 1 could be overly simple for being accurate. I think that one important point was missed. Adoption of data sharing in biomedical research not only implies to provide and re-use the data. It implies to adopt a collaborative approach. It means that when one want to re-use the data of another team, one sometimes must directly contact the other team to have information and to have the data in the appropriate format. Sharing data for a re-analysis of safety outcomes involves sharing the cases report forms while re-using data for some IPD meta-analysis may only rely on sharing data at a later analytical stage (e.g. analysable data). This implies that step 3 is very linked with step 6. I think that the figure will be better (if it is not too complex) by adding such kind of relationship.
- Table 1 , section 1.1.1 / 2.3.1: patients are an important actors/leverages and must be involved in my opinion in these aspects ; -Table 1, in general avoid abbreviations such as "SOP" in 1.3 ; - Table 1 , section 2 and 3.1: Ethic committees have a strong role to play at all these parts. They have, in my opinion to judge wether the de-identification plan is adapted to the specific study ; -Table 1, section 3.2.1: data manager and statisticians must ensure that the code that will be shared works for the de identified data sets. Practical finding from my experience (in one case, de-identification was made after the analysis and labels were different between the two datasets : therefore the shared code didn't worked).
- Table 1 , section 4.1.1: this should be explored before in my opinion (at step 3), when one decide of the data sharing plan.
- Table 2 very interesting, but I would suggest to add an hyperlink to some concrete examples when possible in section 3.
In general the tables should be checked for majuscule and minuscule: eg. table 2, section 3 "during" must 
